EC
LKFT

EcoR1 Capital’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

EcoR1 Capital’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50M Hold
1,667,119
– – 2.12% 11
2025
Q4 		$54.5M Hold
1,667,119
– – 2.47% 10
2025
Q3 		$57.7M Buy
1,667,119
+630,174
+61% +$20.2M 2.77% 11
2025
Q2 		$29M Buy
1,036,945
+881,939
+569% +$23.6M 1.72% 13
2025
Q1 		$3.89M Hold
155,006
– – 0.23% 31
2024
Q4 		$4.26M Hold
155,006
– – 0.16% 45
2024
Q3 		$4.46M Sell
155,006
-5,601,262
-97% -$153M 0.15% 47
2024
Q2 		$143M Hold
5,756,268
– – 4.36% 8
2024
Q1 		$185M Hold
5,756,268
– – 4.69% 6
2023
Q4 		$234M Hold
5,756,268
– – 6.08% 5
2023
Q3 		$199M Hold
5,756,268
– – 6.71% 4
2023
Q2 		$234M Buy
5,756,268
+1,511,623
+36% +$61.7M 5.73% 5
2023
Q1 		$164M Buy
4,244,645
+513,915
+14% +$21.1M 5.28% 4
2022
Q4 		$166M Buy
3,730,730
+533,230
+17% +$22.4M 5.04% 5
2022
Q3 		$136M Hold
3,197,500
– – 4.02% 7
2022
Q2 		$178M Buy
3,197,500
+1,876
+0.1% +$111K 6.16% 5
2022
Q1 		$198M Buy
3,195,624
+971,221
+44% +$59.4M 6.2% 3
2021
Q4 		$123M Buy
2,224,403
+665,654
+43% +$34.7M 3.91% 7
2021
Q3 		$82M Buy
+1,558,749
New +$92.5M 2.85% 9
2021
Q1 		– Sell
-46,666
Closed -$4.62M – 76
2020
Q4 		$4.62M Buy
+46,666
New +$5.71M 0.25% 42
2018
Q1 		– Sell
-110,384
Closed -$10.3M – 32
2017
Q4 		$10.3M Sell
110,384
-130,392
-54% -$12.3M 1.17% 18
2017
Q3 		$24.5M Sell
240,776
-337,729
-58% -$29.5M 3.27% 8
2017
Q2 		$44.3M Buy
578,505
+27,464
+5% +$2.31M 7.86% 5
2017
Q1 		$47.5M Sell
551,041
-10,300
-2% -$742K 12.01% 3
2016
Q4 		$36M Buy
561,341
+60,765
+12% +$3.74M 11.47% 2
2016
Q3 		$32.4M Buy
500,576
+61,191
+14% +$3.45M 9.93% 2
2016
Q2 		$24.4M Buy
439,385
+192,694
+78% +$9.69M 9.61% 2
2016
Q1 		$10.3M Buy
246,691
+79,330
+47% +$3.68M 3.6% 12
2015
Q4 		$10.5M Buy
+167,361
New +$8.55M 3.31% 12

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital's LKFT Position: Q1 2026 in Review

EcoR1 Capital held its Lakefront Biotherapeutics American Depositary Shares (LKFT) position steady in Q1 2026 at 1,667,119 shares worth $50M. The position accounts for 2.12% of the portfolio, ranked #11.

EcoR1 Capital first reported a position in LKFT in Q4 2015 and has held it in 29 quarters since. The position peaked at $234M in Q2 2023. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • EcoR1 Capital held 1,667,119 shares of Lakefront Biotherapeutics American Depositary Shares worth $50M as of Q1 2026.
  • EcoR1 Capital left its Lakefront Biotherapeutics American Depositary Shares share count unchanged in Q1 2026.
  • Lakefront Biotherapeutics American Depositary Shares made up 2.12% of EcoR1 Capital's portfolio in Q1 2026, its #11 holding.
  • EcoR1 Capital first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2015 and has held it in 29 quarters since.
  • EcoR1 Capital's Lakefront Biotherapeutics American Depositary Shares position peaked at $234M in Q2 2023.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on EcoR1 Capital's 13F filing for Q1 2026, filed 15 May 2026.